Samsung Biologics

Samsung Biologics is a fully integrated CDMO partner of choice, providing highly tailored solutions to clients while meeting the evolving needs of the global healthcare industry. With proven regulatory approvals, we provide seamless offerings from cell-line development to final fill/finish at every stage for biopharmaceutical products. Our plants are cGMP compliant with a wide range of bioreactor scales to serve varying client needs and meet growing market demand. We hold a total capacity of 604KL at Bio Campus I, the world’s largest biomanufacturing site, and have announced plans to construct a fifth plant, which will be operational in April 2025.